Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 17/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.49 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 4/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.45 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15816538 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3R1PARP1PIK3CAPIK3CB | |
| SCHEMBL15816755 | 0.86 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15815829 | 0.86 | PIK3CD (0.53) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15816752 | 0.86 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15812629 | 0.84 | ESR1 (0.48) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15812628 | 0.84 | ESR1 (0.48) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15812924 | 0.83 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL15812927 | 0.83 | PIK3CD (0.60) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL17458368 | 0.82 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG | |
| SCHEMBL17458370 | 0.82 | PIK3CD (0.66) | PIK3CDPIK3R1PIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935246-B1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC. | 2016-01-21 | — | — | US | disclosed |
| EP-2935246-A1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | Gilead Calistoga LLC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-9029384-B2 | Phosphatidylinositol 3-kinase inhibitors | Gilead Calistoga, LLC. (US) | 2015-05-12 | — | — | US | disclosed |
| WO-2014100767-A1 | ISOQUINOLINONE OR QUINAZOLINONE PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | GILEAD CALISTOGA LLC (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179718-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3R1 4/4885PARP1 1382/4885 |
| US-20160016915-A1 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS | PIK3R5, PIK3CA, PIK3R4 | PIK3CD 5/4885PIK3R1 4/4885PARP1 1382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.